Alessio Pellegrinelli
University of Pisa
CancerInternal medicinePathologyOncologyGene expression profilingHematologyImmunologyImmunohistochemistryT cellChemotherapyTemozolomideKi-67BevacizumabDiffuse large B-cell lymphomaProgressive diseaseLymphomaGrading (tumors)CetuximabRituximabAdenocarcinomaKRASCancer researchColorectal cancerBioinformaticsMedicineBiologyGastroenterology
38Publications
12H-index
422Citations
Publications 38
Newest
#1Massimo MilioneH-Index: 33
#2Patrick MaisonneuveH-Index: 136
Last. Carlo CapellaH-Index: 86
view all 27 authors...
BACKGROUND: Little information is available concerning prognostic factors of bronchopulmonary large cell neuroendocrine carcinomas (BP-LCNECs) and even less is known about combined LCNECs (Co-LCNECs). We investigated whether an integrated morphological, immunohistochemical and molecular approach could be used for their prognostic evaluation. METHODS: Morphological (including combined features), proliferative (mitotic count/Ki-67 index), immunohistochemical (napsin A, p-40, TTF-1, CD44, OTP, SSTR...
Source
#1Giovanni CentonzeH-Index: 12
#2Vincenzo LaganoH-Index: 2
Last. Massimo MilioneH-Index: 33
view all 19 authors...
High-grade Gastroenteropancreatic Neuroendocrine neoplasms (H-NENs) comprehend well-differentiated tumors (NET G3) and poorly differentiated carcinomas (NEC) with proliferative activity indexes as mitotic count (MC) >20 mitoses/10 HPF and Ki-67 >20%. At present, no specific therapy for H-NENs exists and the several evidences of microenvironment involvement in their pathogenesis pave the way for tailored therapies. Forty-five consecutive cases, with available information about T-cell, immune, and...
Source
#1Adele BusicoH-Index: 16
#2Patrick MaisonneuveH-Index: 136
Last. Massimo MilioneH-Index: 33
view all 17 authors...
Background: In gastroenteropancreatic (GEP) high-grade neuroendocrine neoplasms (H-NENs), Ki-67 threshold of 55%, instead of 20%, defines three prognosis subclasses: neuroendocrine tumor (NET) G3, neuroendocrine carcinoma (NEC) <55% and NEC ≥55%. We investigated whether the molecular profiling of H-NENs differ among these sub-categories and evaluated potential therapeutic targets, including PD-L1. Methods: In consecutive GEP-NEN patients we evaluated: i) 55% threshold for Ki-67 labelling index f...
Source
#1Giovanni CentonzeH-Index: 12
#2Alessandro Mangogna (Health Science University)H-Index: 10
Last. Massimo MilioneH-Index: 33
view all 20 authors...
Gastroblastoma (GB) is a rare gastric epithelial-mesenchymal neoplasm, first described by Miettinen et al. So far, all reported cases described the tumor in children or young adults, and similarities with other childhood blastomas have been postulated. We report a case of GB in a 43-year-old patient with long follow up and no recurrence up to 100 months after surgery. So far, this is the second case of GB occurring in the adult age >40-year-old. Hence, GB should be considered in the differential...
Source
#6Giovanna TagliabueH-Index: 3
: Microenvironment-related immune and inflammatory markers, when combined with established Ki-67 and morphology parameters, can improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs). Therefore, we evaluated the prognostic value of microenvironment and tumor inflammatory features (MoTIFs) in GEP-NENs. For this purpose, formalin-fixed paraffin-embedded tissue sections from 350 patients were profiled by immunohistochemistry for immune, inflammatory, angiogene...
Source
#5Wing C. Chan (City of Hope National Medical Center)H-Index: 86
© 2019 Wiley Periodicals, Inc. The histological diagnosis of peripheral T-cell lymphoma (PTCL) can represent a challenge, particularly in the case of closely related entities such as angioimmunoblastic T-lymphoma (AITL), PTCL-not otherwise specified (PTCL-NOS), and ALK-negative anaplastic large-cell lymphoma (ALCL). Although gene expression profiling and next generations sequencing have been proven to define specific features recurrently associated with distinct entities, genomic-based stratific...
Source
#1Alberto MussettiH-Index: 13
Last. Vittorio MontefuscoH-Index: 33
view all 7 authors...
Symptomatic multiple myeloma (MM) is a plasma cell neoplasm that represents the final stage of a continuum of clinical conditions that start from monoclonal gammopathy of unknown significance (MGUS), then transits in the more advance, but still asymptomatic, smoldering MM (SMM), with a final evolution in symptomatic MM. To investigate SMM microenvironment modifications, we studied 16 patients diagnosed at our hospital. Eight of them (group A) developed MM within 2 years from diagnosis while the ...
Source
#1Massimo MilioneH-Index: 33
#2Patrick Maisonneuve (IEO: European Institute of Oncology)H-Index: 136
Last. Vincenzo Mazzaferro (University of Milan)H-Index: 90
view all 11 authors...
Abstract In pancreatic neuroendocrine neoplasms (pNEN), size ≤2 cm and Ki-67 20%. Tumor size (≤2 vs. >2 cm) was not a predictive factor at any analysis. Intra-class correlation of Ki-67 values on pre-surgical biopsies vs. surgical specimens was 0.99 and Ki-67 classes were correctly identified in 97% of biopsies. Ki-67 and presence of liver metastases are the major prognostic factors in pNEN and identify different progression risks regardless of tumor size. Pre-surgical pNEN biopsy for Ki-67 asse...
Source
#1Anna DoderoH-Index: 21
#2Anna Guidetti (University of Milan)H-Index: 17
Last. Paolo Corradini (University of Milan)H-Index: 96
view all 19 authors...
Source
Historically, the differential diagnosis between different nodal peripheral T-cell lymphoma (PTCL) subtypes based on morphological and phenotypic grounds has posed great challenges. In the last few years, our knowledge of the molecular bases of different PTCLs has significantly expanded. However, peripheral T-cell lymphomas not otherwise specified (PTCL-NOSs) are still regarded to as a heterogeneous category encompassing PTCL cases not fitting other, more homogeneous, subtypes. In fact, PTCL-NOS...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.